ACR-2316 Achieves Complete Tumor Regression in Preclinical Combo, ACR-368 Shows ADC Synergy
ACRV sits 61% above its 52-week low of $1.05.
Summary
Acrivon Therapeutics announced compelling preclinical data for its clinical-stage drug candidates, ACR-368 and ACR-2316, slated for presentation at the 2026 AACR Annual Meeting. The data revealed ACR-368, a CHK1/2 inhibitor currently in a registrational-intent Phase 2b study, exhibited potent synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used as payloads in antibody-drug conjugates (ADCs). Separately, ACR-2316, a WEE1/PKMYT1 inhibitor in Phase 1, demonstrated complete and durable tumor regression in immunocompetent mouse models when combined with anti-PD-L1 checkpoint inhibition. These strong preclinical findings validate Acrivon's proprietary AP3 platform and suggest significant potential for these assets in combination therapies, which could substantially expand their addressable market and improve clinical efficacy. For a small-cap biotechnology company, such positive data supporting enhanced therapeutic strategies for pipeline assets is a material development. Investors will now closely watch for future clinical trial designs that incorporate these promising combination approaches and the continued progression of both ACR-368 and ACR-2316 through their respective clinical development stages.
At the time of this announcement, ACRV was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $52.4M. The 52-week trading range was $1.05 to $5.65. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.